CN103655965B - A kind of pharmaceutical composition and application thereof for the treatment of mycoplasma pneumonia - Google Patents
A kind of pharmaceutical composition and application thereof for the treatment of mycoplasma pneumonia Download PDFInfo
- Publication number
- CN103655965B CN103655965B CN201310710222.8A CN201310710222A CN103655965B CN 103655965 B CN103655965 B CN 103655965B CN 201310710222 A CN201310710222 A CN 201310710222A CN 103655965 B CN103655965 B CN 103655965B
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- mycoplasma pneumonia
- herba
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 title claims abstract description 26
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 239000008187 granular material Substances 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 abstract description 18
- 206010011224 Cough Diseases 0.000 abstract description 11
- 206010037660 Pyrexia Diseases 0.000 abstract description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000008033 biological extinction Effects 0.000 abstract description 5
- 206010047700 Vomiting Diseases 0.000 abstract description 4
- 230000008673 vomiting Effects 0.000 abstract description 4
- 229960003276 erythromycin Drugs 0.000 abstract description 3
- 230000002685 pulmonary effect Effects 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- 239000000843 powder Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000004375 Dextrin Substances 0.000 description 12
- 229920001353 Dextrin Polymers 0.000 description 12
- 235000019425 dextrin Nutrition 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000012567 medical material Substances 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010013786 Dry skin Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010035724 Pneumonia mycoplasmal Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 208000013219 diaphoresis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000723281 Ephedra equisetina Species 0.000 description 1
- 241000218670 Ephedraceae Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 241000596151 Iris domestica Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 244000207740 Lemna minor Species 0.000 description 1
- 235000006439 Lemna minor Nutrition 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 240000002924 Platycladus orientalis Species 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000758742 Saururaceae Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000037306 mature skin Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 201000006509 pleuropneumonia Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of pharmaceutical composition and application thereof for the treatment of mycoplasma pneumonia, said composition is prepared from by the Chinese crude drug of following weight portion: Herba Houttuyniae 26-40 part, Rhizoma Belamcandae 26-40 part, Cacumen Platycladi 18-30 part, Radix Scutellariae 15-25 part, Herba Spirodelae 18-30 part, Pericarpium Citri Reticulatae 18-30 part, Herba Ephedrae 8-16 part, Cortex Moutan 8-16 part.Pharmaceutical composition associating erythromycin for treating mycoplasma pneumonia in children of the present invention, effectively can shorten patient's fever time, cough extinction time, pulmonary's sound of vomiting sound extinction time, alleviate the misery of infant.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of mycoplasma pneumonia, particularly relate to a kind of Chinese medicine composition and application thereof of child for treatment mycoplasma pneumonia, belong to technical field of Chinese medicines.
Background technology
Mycoplasma pneumoniae is the pathogenic former of mycoplasma pneumonia in children, this is a kind of between antibacterial and virus " microorganism of pleuropneumonia sample ", the immune impairment of multisystem is caused after infection, the impaired of body's immunity is healed difficult to the recurrent exerbation and delay that cause other accompanying infections and mycoplasma pneumoniae pneumonia, and serious mycoplasma pneumonia can cause infant dead.In the past traditional Therapeutic Method first-selected macrolide antibiotics, particularly azithromycin, because its tissue penetration is strong, in lung tissue concentration higher, can infiltrate in cell thus effectively kill pathogen.But because the pathogenesis of mycoplasma pneumonia is relevant with direct toxic action and immune impairment, therefore application Macrocyclolactone lactone kind medicine easily occurs that treatment is not thorough, can not remove cause of disease completely, cause the state of an illness easily to recur.And in recent years along with the increase of mycoplasma infection sickness rate, antibiotic abuse, makes the drug resistance of human body increase, thus causes therapeutic effect constantly to reduce.
Summary of the invention
In view of the deficiencies in the prior art, the object of the invention is to, by prescription again after studying Chinese medicine pharmacology, provide a kind of pharmaceutical composition and application thereof for the treatment of mycoplasma pneumonia.
The object of the present invention is achieved like this:
Treat a pharmaceutical composition for mycoplasma pneumonia, be prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Houttuyniae 26-40 part, Rhizoma Belamcandae 26-40 part, Cacumen Platycladi 18-30 part, Radix Scutellariae 15-25 part, Herba Spirodelae 18-30 part, Pericarpium Citri Reticulatae 18-30 part, Herba Ephedrae 8-16 part, Cortex Moutan 8-16 part.
Preferably, described a kind of pharmaceutical composition for the treatment of mycoplasma pneumonia, is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Houttuyniae 30-35 part, Rhizoma Belamcandae 30-35 part, Cacumen Platycladi 22-28 part, Radix Scutellariae 18-22 part, Herba Spirodelae 22-28 part, Pericarpium Citri Reticulatae 22-28 part, Herba Ephedrae 10-14 part, Cortex Moutan 10-14 part.
In the present invention's most preferred embodiment, the pharmaceutical composition of described treatment mycoplasma pneumonia is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Houttuyniae 32 parts, Rhizoma Belamcandae 32 parts, Cacumen Platycladi 25 parts, Radix Scutellariae 20 parts, 25 parts, Herba Spirodelae, Pericarpium Citri Reticulatae 25 parts, 12 parts, Herba Ephedrae, Cortex Moutan 12 parts.
The pharmaceutical composition of any one treatment mycoplasma pneumonia above-mentioned, it is oral liquid, granule, tablet or capsule; Preferably, the pharmaceutical composition of any one treatment mycoplasma pneumonia above-mentioned, it is granule.
Found by experimental study, the effect highly significant of medicine composite for curing mycoplasma pneumonia of the present invention.Therefore, second object of the present invention is to provide a kind of pharmaceutical applications, i.e. the application of aforementioned pharmaceutical compositions in the medicine of preparation treatment mycoplasma pneumonia.Especially it should be noted that, pharmaceutical composition of the present invention is more suitable for the medicine preparing treatment mycoplasma pneumonia in children.
Above-mentioned each Chinese crude drug is prepared into the preparation method of compound granule of the present invention, comprise the steps: to take by recipe quantity the Herba Houttuyniae 26-40 part cleaned up, Rhizoma Belamcandae 26-40 part, Cacumen Platycladi 18-30 part, Radix Scutellariae 15-25 part, Herba Spirodelae 18-30 part, Pericarpium Citri Reticulatae 18-30 part, Herba Ephedrae 8-16 part and Cortex Moutan 8-16 part, merge, decoct with water twice, first time adds water as 10 times amount of medical material weight, decoct 1.5h, second time adds water as 8 times amount of medical material weight, decoct 1.5h, collecting decoction, 0.07MPa, when being evaporated to 65 DEG C at 60-70 DEG C, relative density is the extractum of 1.15, adding 95% (v/v) ethanol makes alcohol content reach 75% (v/v), stir, leave standstill 24 hours, filter, filtrate is at 0.07MPa, under 65 DEG C of conditions, concentrating under reduced pressure one-tenth is 1.25 to relative density when 65 DEG C, and reclaim ethanol, obtain concentrated solution, by concentrated solution spraying dry, (condition is inlet temperature is 100 DEG C, leaving air temp is 80 DEG C, temperature of charge is 80 DEG C, atomizing pressure is 0.2 MPa, spray velocity is 5ml/s.), pulverize 80 mesh sieves, obtain clear paste powder; According to clear paste powder: the weight ratio of dextrin 1:1 ~ 3 takes clear paste powder, dextrin and appropriate 55% ethanol, wherein 55% ethanol refers to that volumetric concentration is the ethanol water of 55%, clear paste powder and dextrin are dropped in trough type mixing machine, stirring 20 minutes, slowly adding 55% ethanol while stirring, to making soft material, granulate with 12 order stainless steel sifts, 65 ~ 75 DEG C of dryings 2 hours, take out, cool and obtain described granule.
Chinese crude drug selected by the present invention has following pharmacologically active and function cures mainly:
Herba Houttuyniae: heat-clearing and toxic substances removing, inducing diuresis to remove edema; Control pneumonia, lung abscess, hematodiarrhoea, malaria, edema, gonorrhea, leucorrhea, carbuncle, hemorrhoid, proctoptosis, eczema, tinea alba, scabies; Select the drying water upper part of Saururaceae herbaceos perennial Herba Houttuyniae; Folium Bambusae: clearing heat and relieving fidgetness, diuresis of promoting the production of body fluid;
Rhizoma Belamcandae: heat-clearing and toxic substances removing, expectorant, sore-throat relieving; For the pent-up of pyretic toxicity phlegm-fire, laryngopharynx swelling and pain, accumulation and obstruction of sputum, cough and asthma; Select irides Rhizoma Belamcandae Belamcandachinensis(L.) dry rhizome of DC.;
Cacumen Platycladi: there is cooling blood for hemostasis, wet down of dispeling the wind, preventing phlegm from forming and stopping coughing, effect of Sweeling-eliminating medicine powder poison; Cure mainly spitting of blood, spit blood, epistaxis, hematuria, dysentery, discharging fresh blood stool, metrorrhagia, rheumatic arthralgia, cough with copious phlegm, erysipelas, mumps, scald; Select the dry browse of Cupressaceae plant Cacumen Platycladi Platycladusorientalis (L.) Franco;
Radix Scutellariae: heat clearing and damp drying, eliminating fire and detoxication, hemostasis, antiabortive, blood pressure lowering.For hygropyrexia, fever disease in summer vomiting and nausea uncomfortable in chest, damp and hot feeling of fullness, dysentery, jaundice, cough due to lung-heat, high hot excessive thirst, heat in blood tells nosebleed, carbuncle sore tumefacting virus, frequent fetal movement; Select the dry root of labiate Radix Scutellariae ScutellariabaicalensisGeorgi;
Herba Spirodelae: diaphoresis, dispels the wind, row water, heat clearing away, removing toxic substances.Row hot carbuncle when controlling, macule is not saturating, wind heat pain rash, skin pruritus, edema, amenorrhea, skin ulcer tinea, and erysipelas, scalds; Select the herb of the blue or green duckweed of plant and of its applications;
Pericarpium Citri Reticulatae: there is regulating qi-flowing for strengthening spleen, in tune, dampness, the effect of reducing phlegm; Cure mainly distension and fullness in the abdomen or pain, the dyspepsia of stagnation of QI in spleen and stomach; Abdominal distention uncomfortable in chest in turbid damp resistance, indigestion and loss of appetite loose stool; Phlegm-damp stops up the cough and asthma of lung; Select the dry mature skin for rutaceae orange and variety thereof;
Herba Ephedrae: diaphoresis cold expelling, depressed lung-energy dispersing, inducing diuresis to remove edema; Be used for chill exterior syndrome, uncomfortable in chestly breath with cough, edema due to wind pathogen edema, rheumatic arthralgia, carbuncle of yin nature, sucutaneous nodule; Select as Ephedraceae plant plait Herba Ephedrae EphedrasinicaStapf, the herb stem of epheday intermedia EphedraintermediaSchrenketC.A.Mey. or ephedra equisetina EphedraequisetinaBge.;
Cortex Moutan: clearing away heat and cooling blood, blood circulation promoting competent silt; For maculae caused by violent heat pathogen, tell, be defeated in battle, have blood in stool, hectic fever due to YIN-deficiency consumptive fever, amenorrhea dysmenorrhea, carbuncle sore tumefacting virus, falls and flutters the pain of injury; Select the root bark of Ranunculaceae perennial machaka plant Paeonia suffruticosa PaeoniasuffruticosaAndr..
Compared with prior art, pharmaceutical composition associating erythromycin for treating mycoplasma pneumonia in children of the present invention, improves curative effect, reduces untoward reaction, especially effectively can shorten patient's fever time, cough extinction time, pulmonary's sound of vomiting sound extinction time, alleviate the misery of infant.
Detailed description of the invention
Be below specific embodiments of the invention, technical scheme of the present invention is done to describing further, but protection scope of the present invention be not limited to these embodiments.Every do not deviate from the present invention's design change or equivalent substituting include within protection scope of the present invention.
the preparation of embodiment 1 Chinese medicine granules
Take the Herba Houttuyniae 32 parts cleaned up, Rhizoma Belamcandae 32 parts, Cacumen Platycladi 25 parts, Radix Scutellariae 20 parts, 25 parts, Herba Spirodelae, Pericarpium Citri Reticulatae 25 parts, 12 parts, Herba Ephedrae and Cortex Moutan 12 parts, merge, decoct with water twice, first time adds water as 10 times amount of medical material weight, decoct 1.5h, second time adds water as 8 times amount of medical material weight, decoct 1.5h, collecting decoction, 0.07MPa, when being evaporated to 65 DEG C at 60-70 DEG C, relative density is the extractum of 1.15, adding 95% (v/v) ethanol makes alcohol content reach 75% (v/v), stir, leave standstill 24 hours, filter, filtrate is at 0.07MPa, under 65 DEG C of conditions, concentrating under reduced pressure one-tenth is 1.25 to relative density when 65 DEG C, and reclaim ethanol, obtain concentrated solution, by concentrated solution spraying dry, (condition is inlet temperature is 100 DEG C, leaving air temp is 80 DEG C, temperature of charge is 80 DEG C, atomizing pressure is 0.2 MPa, spray velocity is 5ml/s.), pulverize 80 mesh sieves, obtain clear paste powder; According to clear paste powder: the weight ratio of dextrin 1:3 takes clear paste powder, dextrin and appropriate 55% ethanol, wherein 55% ethanol refers to that volumetric concentration is the ethanol water of 55%, clear paste powder and dextrin are dropped in trough type mixing machine, stirs 20 minutes, slowly add 55% ethanol while stirring, to making soft material, granulate with 12 order stainless steel sifts, 65 ~ 75 DEG C of dryings 2 hours, take out, cool and obtain described granule, by every bag of 10g packaging.
the preparation of embodiment 2 Chinese medicine granules
Take the Herba Houttuyniae 40 parts cleaned up, Rhizoma Belamcandae 27 parts, Cacumen Platycladi 20 parts, Radix Scutellariae 25 parts, 29 parts, Herba Spirodelae, Pericarpium Citri Reticulatae 18 parts, 10 parts, Herba Ephedrae and Cortex Moutan 15 parts, merge, decoct with water twice, first time adds water as 10 times amount of medical material weight, decoct 1.5h, second time adds water as 8 times amount of medical material weight, decoct 1.5h, collecting decoction, 0.07MPa, when being evaporated to 65 DEG C at 60-70 DEG C, relative density is the extractum of 1.15, adding 95% (v/v) ethanol makes alcohol content reach 75% (v/v), stir, leave standstill 24 hours, filter, filtrate is at 0.07MPa, under 65 DEG C of conditions, concentrating under reduced pressure one-tenth is 1.25 to relative density when 65 DEG C, and reclaim ethanol, obtain concentrated solution, by concentrated solution spraying dry, (condition is inlet temperature is 100 DEG C, leaving air temp is 80 DEG C, temperature of charge is 80 DEG C, atomizing pressure is 0.2 MPa, spray velocity is 5ml/s.), pulverize 80 mesh sieves, obtain clear paste powder; According to clear paste powder: the weight ratio of dextrin 1:3 takes clear paste powder, dextrin and appropriate 55% ethanol, wherein 55% ethanol refers to that volumetric concentration is the ethanol water of 55%, clear paste powder and dextrin are dropped in trough type mixing machine, stirs 20 minutes, slowly add 55% ethanol while stirring, to making soft material, granulate with 12 order stainless steel sifts, 65 ~ 75 DEG C of dryings 2 hours, take out, cool and obtain described granule, by every bag of 10g packaging.
the preparation of embodiment 3 Chinese medicine granules
Take the Herba Houttuyniae 26 parts cleaned up, Rhizoma Belamcandae 26 parts, Cacumen Platycladi 30 parts, Radix Scutellariae 18 parts, 20 parts, Herba Spirodelae, Pericarpium Citri Reticulatae 30 parts, 16 parts, Herba Ephedrae and Cortex Moutan 8 parts, merge, decoct with water twice, first time adds water as 10 times amount of medical material weight, decoct 1.5h, second time adds water as 8 times amount of medical material weight, decoct 1.5h, collecting decoction, 0.07MPa, when being evaporated to 65 DEG C at 60-70 DEG C, relative density is the extractum of 1.15, adding 95% (v/v) ethanol makes alcohol content reach 75% (v/v), stir, leave standstill 24 hours, filter, filtrate is at 0.07MPa, under 65 DEG C of conditions, concentrating under reduced pressure one-tenth is 1.25 to relative density when 65 DEG C, and reclaim ethanol, obtain concentrated solution, by concentrated solution spraying dry, (condition is inlet temperature is 100 DEG C, leaving air temp is 80 DEG C, temperature of charge is 80 DEG C, atomizing pressure is 0.2 MPa, spray velocity is 5ml/s.), pulverize 80 mesh sieves, obtain clear paste powder; According to clear paste powder: the weight ratio of dextrin 1:2.5 takes clear paste powder, dextrin and appropriate 55% ethanol, wherein 55% ethanol refers to that volumetric concentration is the ethanol water of 55%, clear paste powder and dextrin are dropped in trough type mixing machine, stirs 20 minutes, slowly add 55% ethanol while stirring, to making soft material, granulate with 12 order stainless steel sifts, 65 ~ 75 DEG C of dryings 2 hours, take out, cool and obtain described granule, by every bag of 10g packaging.
embodiment 4 Chinese medicine granules is studied the clinical trial of mycoplasma pneumonia in children
Mycoplasma pneumonia in children diagnostic criteria: heating, continuing vigorous is coughed, and x-ray finding is remarkable far beyond sign.Leukocyte normally or slightly increases mostly.Penicillin or cephalosporins invalid.Mycoplasma pneumoniae specific antibody (MP-IGM) is positive or cold agglutinin IGM is positive.
Children with mycoplasma pneumoniae pneumonia 35 example made a definite diagnosis by above-mentioned diagnostic criteria, man 19 example, female 16 example; 1 ~ 3 years old 4 age example, 4 ~ 7 years old 16 example, 8 ~ 16 years old 15 example; The course of disease 3 ~ 19 days.All cases all have cough, the heat that occurs together 19 example, and auscultation of lung has dry moist rales to change 28 examples, and all have x-ray to change, how to change in the form of sheets, following lung is common, and leukocyte raises 8 examples, and CK-MB raises 5 examples.Therapeutic Method: Chinese medicine granules of taking after mixing it with water (being prepared from according to the prescription of embodiment 1 and technique), each 1/3 bag of 1-3 year, each half bag of 4-7 year, each 1 bag of 8-15 year, equal 3 times/day oral.7 days courses for the treatment of.Erythromycin selected by antibiotic, and consumption is 30 ~ 50mg/kg every day.After treating a course for the treatment of, by following curative effect judging standard statistical result:
Effective: medication 24 hours clinical symptoms are clearly better, and 72 hours without clinical symptoms;
Effective: medication 48 hours clinical symptoms are clearly better, and 96 hours without clinical symptoms;
Invalid: medication 72 hours clinical symptoms are without being clearly better or increasing the weight of.
Therapeutic outcome: all infants are all cured, obvious effective rate is 97.43%.Symptom improve situation: treatment group bring down a fever 19 example, average fever time 2.50 ± 0.48 days; Cough-relieving 35 example, 4.87 ± 1.92 days average cough-relieving time; Pulmonary's sound of vomiting sound disappearance 27 example, average extinction time 3.3 ± 1.8 days.In addition, all infant blood, urine, stool routine examination, rabat, liver function, all no abnormal after myocardium enzyme treatment.
Claims (3)
1. treat a pharmaceutical composition for mycoplasma pneumonia, it is characterized in that being prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Herba Houttuyniae 32 parts, Rhizoma Belamcandae 32 parts, Cacumen Platycladi 25 parts, Radix Scutellariae 20 parts, 25 parts, Herba Spirodelae, Pericarpium Citri Reticulatae 25 parts, 12 parts, Herba Ephedrae, Cortex Moutan 12 parts.
2. treat the pharmaceutical composition of mycoplasma pneumonia according to claim 1, it is characterized in that: described pharmaceutical composition is oral formulations.
3. treat the pharmaceutical composition of mycoplasma pneumonia according to claim 2, it is characterized in that: described oral formulations is oral liquid, granule, tablet or capsule.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510840841.8A CN105250537A (en) | 2013-12-22 | 2013-12-22 | Method for preparing drug composition granules for treating mycoplasma pneumonia |
| CN201310710222.8A CN103655965B (en) | 2013-12-22 | 2013-12-22 | A kind of pharmaceutical composition and application thereof for the treatment of mycoplasma pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310710222.8A CN103655965B (en) | 2013-12-22 | 2013-12-22 | A kind of pharmaceutical composition and application thereof for the treatment of mycoplasma pneumonia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510840841.8A Division CN105250537A (en) | 2013-12-22 | 2013-12-22 | Method for preparing drug composition granules for treating mycoplasma pneumonia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103655965A CN103655965A (en) | 2014-03-26 |
| CN103655965B true CN103655965B (en) | 2016-01-20 |
Family
ID=50295524
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510840841.8A Withdrawn CN105250537A (en) | 2013-12-22 | 2013-12-22 | Method for preparing drug composition granules for treating mycoplasma pneumonia |
| CN201310710222.8A Active CN103655965B (en) | 2013-12-22 | 2013-12-22 | A kind of pharmaceutical composition and application thereof for the treatment of mycoplasma pneumonia |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510840841.8A Withdrawn CN105250537A (en) | 2013-12-22 | 2013-12-22 | Method for preparing drug composition granules for treating mycoplasma pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105250537A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105477287A (en) * | 2015-12-24 | 2016-04-13 | 刘子成 | Traditional Chinese medicine preparation for treating weakened-body-resistance and verging-on-desertion type mycoplasmal pneumonia and preparation method thereof |
| CN105434974A (en) * | 2016-01-29 | 2016-03-30 | 山东电力中心医院 | Traditional Chinese medicine composition for treating mycoplasma pneumonia and preparation method |
| CN109620918A (en) * | 2019-01-17 | 2019-04-16 | 昆明市中医医院 | A kind of drug and preparation method thereof for treating pneumonia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101099787A (en) * | 2007-08-13 | 2008-01-09 | 张文芳 | Traditional Chinese medicinal composition with remarkable wide-spectrum antiviral action |
-
2013
- 2013-12-22 CN CN201510840841.8A patent/CN105250537A/en not_active Withdrawn
- 2013-12-22 CN CN201310710222.8A patent/CN103655965B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101099787A (en) * | 2007-08-13 | 2008-01-09 | 张文芳 | Traditional Chinese medicinal composition with remarkable wide-spectrum antiviral action |
Non-Patent Citations (1)
| Title |
|---|
| 小儿肺炎中医治疗进展;王理群;《中医儿科杂志》;20061231;第2卷(第4期);50-53 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105250537A (en) | 2016-01-20 |
| CN103655965A (en) | 2014-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101474286B (en) | Tablet for treating common cold | |
| CN102657805A (en) | Loquat scented tea and preparation technology thereof | |
| CN103655965B (en) | A kind of pharmaceutical composition and application thereof for the treatment of mycoplasma pneumonia | |
| CN102293912B (en) | Chinese medicine for treating pneumonia | |
| CN102366465A (en) | Sanhuangqingjie pharmaceutical composition and preparation method thereof | |
| CN105233116A (en) | Traditional Chinese medicine composition for preventing and controlling respiratory tract infection of chicken and preparation method thereof | |
| CN101129872A (en) | Powder of phellodendron amurense adlay erysipelas | |
| CN100467018C (en) | Jinlian Qingre capsule and its preparation method | |
| CN101954022B (en) | Chinese medicinal composition for treating lung cancer | |
| CN101708286B (en) | Chinese patent medicament for treating sjogren's syndrome and intractable oral ulcer, and preparation method thereof | |
| CN101129627A (en) | Traditional Chinese medicine formulated product for treating post partum toxin fever | |
| CN103463399B (en) | Medicament for treating infantile asthma and preparation method thereof | |
| CN106237039A (en) | A kind of antibacterial cream of rhinitis and preparation method thereof | |
| CN109045164A (en) | A kind of application of pharmaceutical composition in the drug of preparation treatment pneumonia | |
| CN103463401B (en) | Asthma medicine for infants | |
| CN105250791A (en) | Medicine used for treating infantile pneumonia caused by exogenous wind pathogens | |
| CN105012447A (en) | Medicine for treating qi-blood deficiency vulval swelling | |
| CN105148078A (en) | Medicinal preparation used for treating oral ulcers | |
| CN104825984A (en) | Traditional Chinese medicine capsules for treating cervicitis and preparing method thereof | |
| CN104606401A (en) | Medicament for treating umbilical abscess | |
| CN105031364A (en) | Preparation for preventing and treating toothache due to wind-fire evil and preparation method of preparation | |
| CN103566226B (en) | Traditional Chinese medicament for treating suppurative pneumonia | |
| CN104587021A (en) | External application preparation for treatment of umbilical carbuncle | |
| CN103989953A (en) | Traditional Chinese medicinal composition for treating infantile paralysis | |
| CN103230464B (en) | Dai medical mixture for treating cough |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151105 Address after: 276017 Shandong city of Linyi province high tech Zone Technology Park Road bimonthly A321 Linyi grass beauty medicine science and Technology Co Ltd Applicant after: Yang Xianmei Address before: 266200 Jimo, Qingdao, the Yellow River, No. two, No. Road, building 25, building 182 Applicant before: Wang Xueyan |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151130 Address after: 276017 Shandong city of Linyi province high tech Zone Technology Park Road bimonthly A321 Linyi grass beauty medicine science and Technology Co Ltd Applicant after: Yang Xianmei Applicant after: Zhang Xia Address before: 276017 Shandong city of Linyi province high tech Zone Technology Park Road bimonthly A321 Linyi grass beauty medicine science and Technology Co Ltd Applicant before: Yang Xianmei |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160726 Address after: 276017 Shandong city of Linyi province high tech Zone Technology Park Road bimonthly A321 Linyi grass beauty medicine science and Technology Co Ltd Patentee after: Yang Xianmei Address before: 276017 Shandong city of Linyi province high tech Zone Technology Park Road bimonthly A321 Linyi grass beauty medicine science and Technology Co Ltd Patentee before: Yang Xianmei Patentee before: Zhang Xia |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170607 Address after: 226000, 9 Jiangsu Road, Binjiang fine chemical industry zone, Nantong, Jiangsu, Qidong Patentee after: NANTONG FINC PHARMACEUTICAL CHEMICAL Co.,Ltd. Address before: 276017 Shandong city of Linyi province high tech Zone Technology Park Road bimonthly A321 Linyi grass beauty medicine science and Technology Co Ltd Patentee before: Yang Xianmei |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 226000, No.78 Jiangsu Road, Binjiang Fine Chemical Industrial Park, Qidong City, Nantong City, Jiangsu Province Patentee after: Nantong Fayink High-tech Material Technology Co.,Ltd. Address before: 226000 9 Jiangsu Road, Binjiang Fine Chemical Industrial Park, Qidong, Nantong, Jiangsu Patentee before: NANTONG FINC PHARMACEUTICAL CHEMICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231225 Address after: 226000 Qidong Binjiang fine chemical industry park, Nantong City, Jiangsu Province Patentee after: Qidong Binhua water supply Co.,Ltd. Address before: 226000, No.78 Jiangsu Road, Binjiang Fine Chemical Industrial Park, Qidong City, Nantong City, Jiangsu Province Patentee before: Nantong Fayink High-tech Material Technology Co.,Ltd. |